- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00310700
Kinetics of B Cell Response in Infants Menjugate Vaccination
September 18, 2014 updated by: Novartis
A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age
Kinetics of B cell response in infants Menjugate vaccination
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
75
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oxon
-
Oxford, Oxon, United Kingdom, OX3 7LJ
- Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 2 months (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy infants
Exclusion Criteria:
- previously ascertained or suspected disease caused by N. meningitidis
- previous household contact with an individual with a positive culture of N. meningitidis serogroup C
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To establish at which day meningococcal C specific B cells are detectable in the blood of healthy infants following first and third immunisation with MenC Conjugate Vaccine as determined by Men C specific B-cell ELISPot assay.
|
Secondary Outcome Measures
Outcome Measure |
---|
To establish how long the B cells persist in the blood
|
To note the difference between plasma cell response following the first and third MenC vaccination.
|
To determine the immune response to Neisseria meningitidis serogroup C 26-34 days after the third immunisation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Novartis Vaccines - Information Services, Novartis Vaccines & Diagnostics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
November 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
April 3, 2006
First Submitted That Met QC Criteria
April 3, 2006
First Posted (Estimate)
April 4, 2006
Study Record Updates
Last Update Posted (Estimate)
September 19, 2014
Last Update Submitted That Met QC Criteria
September 18, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M14P5
- Impact N° 1457
- 2004-004962-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Meningococcal Infection
-
Novartis VaccinesGlaxoSmithKlineCompletedPrevention of Meningococcal InfectionSpain, Poland
-
Novartis VaccinesCompletedPrevention of Meningococcal InfectionUnited Kingdom
-
NovartisNovartis VaccinesCompletedPrevention of Meningococcal InfectionUnited Kingdom
-
Novartis VaccinesCompletedPrevention of Meningococcal InfectionGermany, Poland
-
NovartisNovartis VaccinesCompletedPrevention of Meningococcal InfectionItaly
-
Novartis VaccinesNovartisCompletedPrevention of Meningococcal DiseaseUnited States
-
Novartis VaccinesCompletedPrevention of Meningococcal DiseaseUnited States
-
Novartis VaccinesGlaxoSmithKlineCompleted
-
Novartis VaccinesNovartisCompletedPrevention of Meningococcal DiseaseCanada, United Kingdom
-
TaiMed Biologics Inc.Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research CenterCompletedPrevention of Infection With HIV-1United States
Clinical Trials on Meningococcal C conjugate vaccine
-
Public Health EnglandInstitute of Child Health; National Institute of Biological Standards and ControlCompletedPneumococcal Infections | Meningococcal InfectionsUnited Kingdom
-
NovartisNovartis VaccinesCompletedPrevention of Meningococcal InfectionItaly
-
Novartis VaccinesGlaxoSmithKlineCompletedPrevention of Meningococcal InfectionSpain, Poland
-
Novartis VaccinesCompletedPrevention of Meningococcal InfectionUnited Kingdom
-
Novartis VaccinesCompletedPrevention of Meningococcal InfectionGermany, Poland
-
NovartisNovartis VaccinesCompletedMeningococcal InfectionGermany
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningococcal Immunisation (Healthy Volunteers)Denmark, Finland, Germany
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdActive, not recruiting
-
Beijing Minhai Biotechnology Co., LtdCompleted